Enfermedades Autoinmunes Sistémicas. Clínica

Dra. Paloma García de la Peña

HOJA DE RUTA-RESUMEN X Y J

- Síndrome antifosfolípido- Lupus eritematoso- Esclerosis sistémica

- Vasculitis- Otras

RUTA DE VIAJE

SÍNDROME ANTIFOSFOLÍPIDOWIN & HOT SESSION 13:30-15:00

Revisión de las manifestaciones clínicas Necesidad de crear unos criterios

diagnósticos≠clasificación

Dr. MuntherKhamasta

Dr. PL Meroni

Nefropatía

Afectación cardiaca

Trombopenia

Trombosis superficiales

Lívedo reticularis

Corea

Mielitis longitudinal

AFFP (-)

Cefalea

Convulsiones

LUPUS ERITEMATOSO SISTÉMICOPOSTER TOUR 11:45-13:30Novelty in the clinical aproach to SLE, Sjögren´s and APS I”

THU0256DEVELOPMENT AND VALIDATION OF A SCORE TO PREDICT THE RISK OF SEVERE INFECTION IN SLEB. Tejera Segura1,*, I. Rúa-Figueroa2, J. Pego-Reigosa3, V. del Campo Pérez3, D. Isenberg1, A. Rahman1

RELESSER

N=3658

DESARROLLO

UCLH

N=699

VALIDACIÓN

14%Infecciones serias

SCORE medio DCO=4,2

SCORE>3,8 S75%-E 50%

LUPUS ERITEMATOSO SISTÉMICOPOSTER TOUR 11:45-13:30“Novelty in the clinical aproach to SLE, Sjögren´s and APS I”

THU0248THE ASSOCIATION BETWEEN SYSTEMIC LUPUS ERYTHEMATOSUS TO BIPOLAR DISORDER A REAL-LIFE STUDYS. Tiosano1,2,*, O. Gendelman1,2, D. Comaneshter3, H. Amital1,2, A. Cohen3,4, D. Amital5

THU0491COMPARISON OF CLINICAL AND SEROLOGICAL FEATURES OF JUVENILE AND ADULT-ONSET NEUROPSYCHIATRIC LUPUS IN SPANISH PATIENTSS. Garrote Corral1,*, A. García Fernández1, W. A. Sifuentes Giraldo1, A. L. Boteanu1, M. L. Gámir Gámir1, A. Zea Mendoza1

C57B//6-lrp mice

N=39 LES/19 controlesExpresión Baja IRAK-M

Receptor IL-1 asociado

M kinasa- Regulador (-) –

TOLL R

LES- Adultos 41 (59%) LES-INF 28 (41%)

Afectación SNC +FREC 93%/96%

Afectación SNP 12%/11%

2 o más manifestaciones 32%/41%THU0224ASSOCIATION OF IRAK-M WITH NEUROPSYCHIATRIC SYMPTOMS IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS.S. Sacre1,*, R. Thwaites1, K. Davies

LUPUS ERITEMATOSO SISTÉMICOPOSTER TOUR 11:45-13:30“Novelty in the clinical aproach to SLE, Sjögren´s and APS I”

THU0247THE PRESENCE OF ANTI-RO AND ANTI-LA ANTIBODIES IS ASSOCIATED WITH TUBULOINTERSTITIAL DAMAGE IN LUPUS NEPHRITISA. Londono Jimenez1,*, W. B. Mowrey 2, A. Broder 3

THU0216URINARY NEUROPILIN-1: A NEW BIOMARKER APPROACH IN THE PROGNOSIS OF LUPUS NEPHRITIS.M. Torres-Salido1, C. Solé-Marcé1,*, M. Vidal2, J. Cortés-Hernández1, J. Ordi-Ros1

10 años 157 NL 25% Afectación M/S TI

Ro+LAFactor independiente/edad/clase NL y FG

70 LES y NL con Proteinuria rango nefrótico/ 25 Nefropatía no lúpica/ 25 controles sanos

LUPUS ERITEMATOSO SISTÉMICOPOSTER TOUR“Novelty in the clinical aproach to SLE, Sjögren´s and APS I”

THU0250EFFECT OF FETAL UMBILICAL ARTERY DOPPLER ON PREDICTION OF ADVERSE PREGNANCY OUTCOMES IN WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUSZ. Zhan1,*, D. Chen1, Q. Qiu1, Y. Yang1

106 pacientes3º trimestre y al final (82)

65 pacientes Efectos adversos

45 partos prematuros

23 CIR

16 distres fetal

8 LES neonatal

3 MalformacionesS/D>2,8

PP/IR/VPFS/VPFD

ESCLEROSIS SISTÉMICAABSTRACTS SESSION 10:15-11:45“Clinical and therapeutical news in Systemic Sclerosis”

OP0123PREDICTION OF PROGRESSIVE SKIN THICKENING IN EARLY DIFFUSE SYSTEMIC SCLEROSIS USING THREE-MONTHLY SKIN SCORES FROM THE EUROPEAN SCLERODERMA OBSERVATIONAL STUDY (ESOS)A. Herrick1,*, S. Peytrignet1, X. Pan1, R. Hesselstrand2, L. Mouthon3, E. Brown1, L. Czirják4, J. H. Distler5, O. Distler6, K. Fligelstone1, W. Gregory1, R. Ochiel7, A. Silman8, M. Vonk9, M. Lunt1, C. Denton7

N=326

TM=11,9

meses

20% Progresores

69,6 No Progresores

¿10%?

22 PUNTO CORTE-sSmR

ESCLEROSIS SISTÉMICAABSTRACTS SESSION 10:15-11:45“Clinical and therapeutical news in Systemic Sclerosis”

OP0128DETECTION OF SUB-CLINICAL DIFFUSE MYOCARDIAL FIBROSIS BY NATIVE T1 MAPPING MAGNETIC RESONANCE IMAGING IN A PROSPECTIVE SYSTEMIC SCLEROSIS COHORTV. Poindron1,*, E. Chatelus1, M. Canuet1, P. Germain1, S. El Ghannudi1, T. Martin1

72 pacientes (38% Escd)

T1 Fibrosis difusa50% (50% Ecocardionormal) 43% fase temprana enfermedad.

T2 edema miocárdico 8,36%Gadolinio Fibrosis focal 25,7%

Forma consecutiva3 años

VASCULITIS/OTRASABSTRACTS SESSION 10:15-11:45“Vasculitis clinical and pathogenic highlights”

OP0133COLOUR DOPPLER ULTRASONOGRAPHY OF FACIAL AND OCCIPITAL ARTERIES IN PATIENTS WITH GIANT CELL ARTERITIS: THE FREQUENCY OF INVOLVEMENT AND THE ROLE OF THEIR ASSESSMENT IN DAILY PRACTICE: A PROSPECTIVE STUDY R. Jese1,*, Ž. Rotar1, M. Tomšič1, A. Hočevar1

POSTER TOUR“Vasculitis clinical aspects”

THU0297A NOVEL ULTRASOUND SCORING SYSTEM FOR GIANT CELL ARTERITISS. Monti1,2,*, C. Ponte3, G. Carrara4, F. Rumi4, A. Hutchings5, B. Dasgupta6, R. Luqmani2

Estudio prospectivo-2años-93 pac. (67% ♀)

Signo halo 41% AFa* y 31% Aoc* ambas 19%

N=135 24% No Dcoconfirmación